binary-catalyst-biotech theme · 36 dossiers

Best-in-class oral TYK2 story sitting near 52-week highs (~$28) as the market waits on the Q3 2026 LUMUS Phase 2b lupus topline — the binary that either re-rates envudeucitinib into a multi-billion indication or caps it as a psoriasis-only…

Precision-psychiatry re-rate (~10x off $2.85) re-armed on 2026-07-13 — a successful FDA meeting cleared an additional ALTO-207 monotherapy Phase 3 in TRD, funded same-day by a $100M raise at $26.48. Narrative refreshed, but every data…

Rumor confirmed and cashed: Eli Lilly is acquiring AtaiBeckley (announced 2026-07-16) for $6.75/share cash plus up to $2.50 CVR tied to BPL-003/VLS-01 milestones. Shares gapped to ~$7.20 and desks cut to Hold en masse — momentum is dead,…

De-rate reversal off the $7.48 Nov-CRL low has stalled near $14 after peaking ~$16 in early July; the opakalim epilepsy pivotal (RISE3) topline is unscheduled 2H-26, sell-side is turning cautious (BofA Underperform $11), and a dilution…

De-levering small-cap orthobiologics turnaround, now maturing: the July-2025 refi killed the 2026 debt wall, margins inflected above 20%, and the stock re-rated ~+117% to within 4% of its 52-week high. The easy money is largely priced; the…

Single-asset immunology binary: barzolvolimab (anti-KIT mast-cell depleter) has both Phase 3 CSU trials fully enrolled six months early, with topline Q4 2026 the coin-flip. Stock ~$35 vs $53 median target, but the tape is range-bound in…

Phase 3 depression win for DT120 already ran +60% in public; a seven-shop $50–$74 target band and a $700M raise at $34 are digested, not fresh. Post-catalyst name maturing under a dilution overhang — the entry is a base that holds $34, not…

Q1 beat-and-raise (adj EPS $0.14 vs $0.09, FY26 guide lifted above $120M, 2026-05-14) confirmed the specialty-pharma rollup, but the story stopped accelerating in mid-May and now drifts through an empty window into the ~August Q2 print —…

CRO margin-turnaround already re-rated FTRE ~4x off its 2025 low; the Q1 beat that drove it is spent and price sits ~9% under the $18.67 52-week high, above most analyst targets. Fresh positive drift (Zacks Strong-Buy 7/7 on +31% estimate…

Post-launch broken-momentum hematology name: RYTELO 2L lower-risk MDS ramp is real but decelerating ($51.8M Q1 net rev, +31% YoY) while price holds near its $1.04 52-week low, below every major MA. The only live re-rate is the…

Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No…

Post-Parkinson's-failure microcap, now a single-asset PAH story (IKT-001 imatinib prodrug). IMPROVE-PAH Phase 3 only began enrolling 2026-04-07, so topline is 2027-2028 and there is no near-term binary. Stock ~$2.23 trades near its ~$200M+…

Near-term regulatory binary resolved favorably — FDA accepted the ozekibart chondrosarcoma BLA on 2026-06-15 (PDUFA 2027-04-14) — but that docketed the defining decision ~9 months out, dropping the name into an extended catalyst vacuum.…

Single-asset MASH binary: lanifibranor's NATiV3 Phase 3 topline (Q4 2026) is the whole equity. The June 2 refinancing cleared the funding overhang (runway into early Q1 2028) and Cantor initiated Overweight July 17. Stock coils on the…

Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B…

ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary —…

Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided…

Single-asset FA binary: nomlabofusp's rolling BLA for accelerated approval is live, but the 2026-06-29 open-label data carried an anaphylaxis signal (10 of 43 patients, ~23%) that turned the filing into a ~17% selloff. Shares drift near…

De-risked Wilson-disease NDA melt-up extended rather than sold the EAN news: a 6.70M-share float ran to fresh all-time highs (~$111 on 2026-07-17) on the June-30 FDA Rare Pediatric Disease designation and clustered analyst PT hikes. The…

The oncology-pivot re-rate (0.55 to 8.00 in twelve months) has stalled: RLMD lost 10.5% on 2026-07-16 and another 4.0% on 2026-07-17 to $5.24, unwinding the Russell-inclusion bid with no dated NDV-01 catalyst before end-2026. Story intact,…

Post-interim re-rating has fully decayed: $4.61 on 2026-07-17 vs the $5.14 late-June high, with no dated event between here and the upLIFT full topline in 2H-2026. A binary rare-disease name in its dead zone — the 6/8 responder signal is…

A record short squeeze (~32% of float) and buyout speculation, now joined by sell-side PT hikes (Alliance Global $10→$25, Jul 17), have carried SLS to a $16 test and back to ~$13; the defining Phase 3 REGAL overall-survival readout stays…

Single-asset ivonescimab binary sitting $1.26 above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…

Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June…

Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 — pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next…

June's volume-backed reclaim to $10.03 failed to extend — $9.43 on Jul 17, -5.3% on the week, with short interest rising to 11.72% of float as shorts pressed the fade. Structure holds above the 50-DMA near $8.71, but nothing hard is dated…

Both Phase 2 trials (TibuSHIELD/HS, TibuSURE/SSc) are now fully enrolled and fresh William Blair + Chardan bull notes landed in early July, but the enrollment-momentum leg has stalled — 2026-07-17 volume ran ~82% below average and price is…

The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…